Issue 45, 2015

Graphene quantum dots for the inhibition of β amyloid aggregation

Abstract

The aggregation of Aβ peptides is a crucial factor leading to Alzheimer's disease (AD). Inhibiting the Aβ peptide aggregation has become one of the most essential strategies to treat AD. In this work, efficient and low-cytotoxicity inhibitors, graphene quantum dots (GQDs) are reported for their application in inhibiting the aggregation of Aβ peptides. Compared to other carbon materials, the low cytotoxicity and great biocompatibility of GQDs give an advantage to the clinical research for AD. In addition, the GQDs may cross the blood–brain barrier (BBB) because of the small size. It is believed that GQDs may be therapeutic agents against AD. This work provides a novel insight into the development of Alzheimer's drugs.

Graphical abstract: Graphene quantum dots for the inhibition of β amyloid aggregation

Supplementary files

Article information

Article type
Paper
Submitted
12 Sep 2015
Accepted
07 Oct 2015
First published
09 Oct 2015

Nanoscale, 2015,7, 19060-19065

Author version available

Graphene quantum dots for the inhibition of β amyloid aggregation

Y. Liu, L. Xu, W. Dai, H. Dong, Y. Wen and X. Zhang, Nanoscale, 2015, 7, 19060 DOI: 10.1039/C5NR06282A

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements